Over the past few years, there seems to be an explosion of attention given to meibomian gland dysfunction/disease (MGD). First described by Dr. Donald Korb and associates (what’s new? He has brought us GPC, lid wiper epitheliopathy, and a host of contact lens designs and ophthalmic instruments and products over the years), MGD has been suggested to be the main cause of dry eye that we see in clinical practice on a daily basis. Primary eye care practitioners have been bombarded with eye drops, pharmaceutical options, home therapies and in-office treatments for MGD. It is no wonder that ECPs often experience “deer in the headlights” syndrome regarding the best way to approach MGD. What treatment is most effective? What order of intervention should I take? Is there an algorithm that I can follow? How much of what is out there is evidence-based with solid science behind it?
If you would like to read this complete article, please sign up to become a member!
You do not have access to this post.
